Noninjectable Insulins Win Approval: Pfizer in the US, Generex in South America

Koroneos, George
March 2006
Pharmaceutical Technology;Mar2006, Vol. 30 Issue 3, p28
Trade Publication
The article reports on the approval of noninjectable insulins in the United States and in South America. Pfizer's Exubera has been approved by the U.S. Food and Drug Administration to treat adults with type 1 and type 2 diabetes. Generex's oral insulin "Oral-lyn" went on the market in Ecuador for the treatment of patients with Type-2 diabetes, and is in clinical trials in Europe.


Related Articles

  • GENEREX ORAL INSULIN SPRAY APPROVED BY LEBANESE GOVERNMENT.  // Worldwide Biotech;Feb2009, Vol. 21 Issue 2, p1 

    The article reports that Lebanon's Ministry of Public Health has given its approval for Generex Biotechnology Corporation's Generex Oral-lyn proprietary oral insulin spray product, for importation, marketing, distribution, and commercial sale in the Republic of Lebanon. The oral insulin spray...

  • First in Bananas and Noninjectable Insulin. Trecroci, D. // Diabetes Health;Jul2005, Vol. 14 Issue 7, p16 

    Reports on the approval of noninjectable insulin formulation from Generex Biotechnology in Ecuador. Estimated number of people with diabetes in the country; Implication of the decision according to the company.

  • New Inhalable Insulin Getting Ready for Clinical Trials.  // Diabetes Health;Sep2006, Vol. 15 Issue 9, p18 

    The article reports on the agreement of Generex Biotechnology Corp. with Cardinal Health Inc. to manufacture clinical trial batches of Generex Oral-Lyn inhalable insulin spray. The agreement is announced on June 22, 2006. Generex Oral-Lyn inhalable insulin spray is already available in Ecuador.

  • Rapid- and slow-acting insulins help control diabetes. Zablocki, Elaine // Managed Healthcare Executive;Jan2006, Vol. 16 Issue 1, p46 

    The article enlightens about the availability of two rapid-acting insulins with a more rapid onset and shorter duration of action than regular insulin to contain blood sugar levels in people with diabetes, whose population is increasing at an alarming rate in the United States. Byetta is a new...

  • Generex wins approval for impaired glucose tolerance study.  // PharmaWatch: Biotechnology;Sep2008, Vol. 7 Issue 9, p13 

    The article reports that the ethics committee of the University Campus Bio-Medico of Rome has approved Generex Biotechnology Corp. to conduct a trial for its oral insulin spray Generex Oral-lyn in Italy. The trial aims to determine whether Generex Oral-lyn reduces the glucose levels of patients...

  • FDA Approves Inhaled Insulin. Trecroci, D. // Diabetes Health;Jul2006, Vol. 15 Issue 7, p37 

    The article reports on the approval provided by the U.S. Federal Drug and Administration to the inhalable insulin Exubera from Pfizer Inc. It is said that Exubera is the first insulin option in the U.S. that does not necessitate to be administered by injection. Pfizer states in a news release...

  • Pfizer obtains complete response letter for anxiety disorder drug.  // PharmaWatch: CNS;Feb2010, Vol. 9 Issue 2, p11 

    The article reports that Pfizer Inc. has received the response letter from the Food and Drug Administration (FDA) regarding the company's new drug application (NDA) for Lyrica capsules, an anxiety disorder drug in the U.S.

  • Financings Roundup.  // BioWorld Today;5/21/2009, Vol. 20 Issue 97, p10 

    The article reports on the consummation by Generex Biotechnology Corp. of a $5 million registered direct offering of the company's common stock to selected accredited investors. The offering of the company's common stock is said to have been at discount, had no warrant coverage and covers about...

  • Deals Roundup.  // BioWorld Today;8/26/2008, Vol. 19 Issue 166, p4 

    The article reports that Generex Biotechnology Corp. and Dong-Sung Pharm Co. Ltd. of South Korea entered into a licensing and distribution agreement. Under the deal, Dong-Sung will market and distribute Generex Oral-lyn, an oral insulin spray product. Dong-Sung will pay nonrefundable, up-front...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics